Head to head
Ceribell vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: CBLL · ABT
CBLL
Ceribell
23.63+2.07%
1-year price shape — +84% over the period
Quant Rating B · 93/100
vs
ABT
Abbott Laboratories
99.60+1.13%
1-year price shape — -24% over the period
Quant Rating D · 16/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| CBLL | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Medical Devices |
| Last price | 23.63 | 99.60 |
| Change today | +2.07% | +1.13% |
| 1-year return | +84.3% | -23.6% |
| Market cap | $906.87M | $172.35B |
| 52-week range | 10.85 – 25.63 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | -13.43 | 32.23 |
| P/E percentile, own 5-yr range | 56th | 62nd |
| P/B | 7.07 | 3.37 |
| Dividend yield | 0.00% | 2.45% |
| Profitability & growth | ||
| EPS (TTM) | -1.46 | 3.72 |
| Net profit (TTM) | $-56.03M | $6.44B |
| Revenue (TTM) | $101.96M | $46.59B |
| Revenue growth (YoY) | +32.5% | +13.0% |
| Gross margin | 88.9% | 56.6% |
| Operating margin | -68.6% | 15.8% |
| Net margin | -64.7% | 11.6% |
| Free cash flow (TTM) | $-54.72M | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 95.6% | 81.1% |
| Insider activity (12mo) | 10 buy / 40 sell | 36 buy / 12 sell |
| Short interest (% of float) | 5.3% | 0.8% |
| Analyst consensus | 100% buy (5) | 100% buy (14) |
| Analyst price target | $30 (+26%) | $126 (+26%) |
| StockVane view | ||
| StockVane Quant Rating | B (93) | D (16) |
| Company | ||
| Employees | 327 | 115,000 |
| Founded | 2014 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.